
Penumbra (PEN) Stock Forecast & Price Target
Penumbra (PEN) Analyst Ratings
Bulls say
Penumbra Inc. achieved significant milestones in December, recording its highest ever volume of Venous Thromboembolism (VTE) procedures, which contributed to an impressive 41% growth as their Flash 2.0 product gained market share in a previously challenging segment. The company's financial performance showed substantial improvement, with a non-GAAP operating margin that increased by 200 basis points year-over-year, supported by enhanced gross margins of 67.4% that surpassed consensus expectations. Additionally, overall Thrombectomy sales reached $222.7 million, reflecting a robust growth of 16.9%, while gross margin improvements were driven by a favorable product mix and enhanced productivity metrics.
Bears say
The analysis of Penumbra Inc.'s outlook reveals concerns regarding a projected decrease in revenue growth to below 12%, driven by limited contributions from new products and slower profitability improvements. Furthermore, revenue estimates for 2025 and 2026 have been reduced from $1.363 billion to $1.349 billion and from $1.545 billion to $1.531 billion, indicating a downward trend in financial performance. Additional risks such as potential competition, operational execution failures, and supply chain disruptions further contribute to the negative sentiment surrounding the stock's future prospects.
This aggregate rating is based on analysts' research of Penumbra and is not a guaranteed prediction by Public.com or investment advice.
Penumbra (PEN) Analyst Forecast & Price Prediction
Start investing in Penumbra (PEN)
Order type
Buy in
Order amount
Est. shares
0 shares